Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study.

Tsai, Wen-Hsuan; Sung, Fung-Chang; Chiu, Lu-Ting; Shih, Ying-Hsiu; Tsai, Ming-Chieh; Wu, Shu-I

Tsai, Wen-Hsuan; Sung, Fung-Chang; Chiu, Lu-Ting; Shih, Ying-Hsiu; Tsai, Ming-Chieh; Wu, Shu-I.

Afiliação

Tsai WH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
Sung FC; Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan.
Chiu LT; Department of Health Services Administration, China Medical University, College of Public Health, Taichung, Taiwan.
Shih YH; Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan.
Tsai MC; Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan.
Wu SI; Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan.

Front Pharmacol ; 13: 886343, 2022.

Article em En | MEDLINE | ID: mdl-35392555

Palavras-chave

anxiety; depression; diabetes; glucagon-like peptide-1 receptor agonist; neuroendocrine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google